Fol. Biol. 2013, 59, 217-224
https://doi.org/10.14712/fb2013059060217
Correlated Increase of Omentin-1 and Adiponectin by Exenatide, Avandamet and Dietary Change in Diet-Induced Obese Rats
References
1. , A. H. (2009) Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc. Health Risk Manag. 5, 141-151.
<https://doi.org/10.2147/VHRM.S4664>
2. , E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., Muggeo, M. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23, 57-63.
<https://doi.org/10.2337/diacare.23.1.57>
3. , A. F., Tartagni, E., Ertek, S. (2012) Metformin and its clinical use: new insights for an old drug in clinical practice. Arch. Med. Sci. 8, 907-917.
<https://doi.org/10.5114/aoms.2012.31622>
4. , B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson C, Sams, A., Knudsen, L. B, Raun, K., Havel, P. J. (2010) Chronic administration of the glucagonlike peptide1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 59, R2653-2661.
<https://doi.org/10.2337/db09-1564>
5. , C. M., Yang, R. Z., Lee, M. J., Glynn, N. M., Yu, D. Z., Pray J, Ndubuizu, K., Patil, S., Schwartz, A., Kligman, M., Fried, S. K., Gong, D. W., Shuldiner, A. R., Pollin, T. I., McLenithan, J. C. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56, 655-661.
<https://doi.org/10.2337/db06-1506>
6. , M., Braga, M. B., Verma S. (2008) A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Can. J. Cardiol. 24, e65-69.
<https://doi.org/10.1016/S0828-282X(08)70685-8>
7. , M., Su, H., Gao, W., Johansson, S. M., Liu, Q., Wu, X., Liao, J., Young, A. A., Bartfai, T., Wang, M. W. (2010) Reversal of obesity and insulin resistance by a nonpeptidic glucagonlike peptide1 receptor agonist in dietinduced obese mice. PLoS One 5, e14205.
<https://doi.org/10.1371/journal.pone.0014205>
8. , N. P., Kapelouzou, A., Tsanikidis, H., Vitta, I., Liapis, C. D., Sailer, N. (2011) Effects of rosiglitazone/ metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119, 63-68.
<https://doi.org/10.1055/s-0030-1265174>
9. , T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., Tobe, K. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792.
<https://doi.org/10.1172/JCI29126>
10. , L., Yang, G., Li, Q., Tan, X., Liu, H., Tang, Y., Boden, G. (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes. Metab. 10, 921-930.
<https://doi.org/10.1111/j.1463-1326.2007.00832.x>
11. , J. M., Catalán, V., Ortega, F., Gómez-Ambrosi, J., Ricart, W., Frühbeck, G., FernándezReal, J. M. (2010) Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 7, 27.
<https://doi.org/10.1186/1743-7075-7-27>
12. , A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S. Jr., Brehm, B. J., Bucher, H. C. (2006) Effects of low- carbohydrate vs lowfat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 285-293.
<https://doi.org/10.1001/archinte.166.3.285>
13. , A., Asghari, M., Ghorbani, A. (2010) Effects of aerobic training on serum omentin1 and cardiometabolic risk factors in overweight and obese men. J. Sports Sci. 28, 993-998.
<https://doi.org/10.1080/02640414.2010.484070>
14. , P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., Bajaj, M. (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19, 2310-2315.
<https://doi.org/10.1038/oby.2011.152>
15. , R., Ouchi, N., Takahashi, R., Terakura, Y., Ohashi, K., Keda, N., Higuchi, A., Terasaki, H., Kihara, S., Murohara, T. (2012) Omentin as a novel biomarker of metabolic risk factors. Diabetol. Metab. Syndr. 26, 37.
<https://doi.org/10.1186/1758-5996-4-37>
16. , D., Fujiwara, Y., Komohara, Y., Mizuta, H., Takeya, M. (2012) Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem. Biophys. Res. Commun. 425, 304-308.
<https://doi.org/10.1016/j.bbrc.2012.07.086>
17. , F. M., de Almeida, J. C., Feoli, A. M. (2011) Effect of diet on adiponectin levels in blood. Nutr. Rev. 69, 599-612.
<https://doi.org/10.1111/j.1753-4887.2011.00414.x>
18. , S., Akhtar, N., Ahmad, J. (2012) Plasma adiponectin levels in women with polycystic ovary syndrome: impact of Metformin treatment in a casecontrol study. Diabetes Metab. Syndr. 6, 207-211.
<https://doi.org/10.1016/j.dsx.2012.05.013>
19. , B. K., Adya, R., Farhatullah, S., Lewandowski, K. C., O’Hare, P., Lehnert, H., Randeva, H. S. (2008) Omentin-1, a novel adipokine, is decreased in overweight insulinresistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin1 by insulin and glucose. Diabetes 57, 801-808.
<https://doi.org/10.2337/db07-0990>
20. , B. K., Adya, R., Farhatullah, S., Chen, J., Lehnert, H., Randeva, H. S. (2010) Metformin treatment may increase omentin1 levels in women with polycystic ovary syndrome. Diabetes 59, 3023-3031.
<https://doi.org/10.2337/db10-0124>
21. , F., Chinello, M. (2010) Exenatide in type 2 diabetes. Lancet 376, 1052-1053.
<https://doi.org/10.1016/S0140-6736(10)61485-7>
22. , S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R., L., Ferrante, A., W. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808.
<https://doi.org/10.1172/JCI200319246>
23. , D., Huang, X. D., Yuan, J., P., Wu, J., Fan, Y., Luo, H. S., Yang, Y. H. (2011) Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD. Hepatogastroenterology 58, 1703-1707.
24. , P., Liu, D., Long, M., Ren, Y., Pang, J., Li, R. (2011a) Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 119, 257-263.
<https://doi.org/10.1055/s-0030-1269912>
25. , P., Li, L., Yang, M., Liu, D., Liu, H., Boden, G., Yang, G. (2011b) Effects of the long-acting human glucagon-like peptide1 analog liraglutide on plasma omentin1 levels in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 92, 368-374.
<https://doi.org/10.1016/j.diabres.2011.02.030>
26. , R. Z., Lee, M. J., Hu, H., Pray, J., Wu, H. B., Hansen, B. C., Shuldiner, A. R., Fried, S. K., McLenithan, J. C., Gong, D.W. (2006) Identification of omentin as a novel depot- specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290, E1253-1261.
<https://doi.org/10.1152/ajpendo.00572.2004>
